Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | AUTO1 CAR-T delivers durable remissions and low toxicity in adult ALL

Claire Roddie • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia AUTO1 CAR-T
ALLCAR19

Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses preliminary data from ALLCAR19 (NCT02935257), a multicenter, phase I clinical study of AUTO1, a novel second generation CD19 CAR-T product, as therapy for relapsed/refractory adult acute lymphoblastic leukemia (ALL). Results show that AUTO1 delivers durable remissions and prolonged CAR T-cell persistence with low cytokine-release syndrome or neurotoxicity in adult ALL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Claire Roddie

1:28
Insights into the UCL CAR T program
Claire Roddie • 3 Jun 2023
Updates in ALL
Bijal Shah et al. • 14 Apr 2023
3:38
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
Claire Roddie • 3 Jun 2023
4:45
Safety and efficacy of obe-cel in R/R adult B-ALL: results of the pivotal FELIX study
Claire Roddie • 3 Jun 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals